Email Updates

Search form

You are here

How to evaluate PrEP and vaccines: urgency for next generation compounds

Include in
Media Coverage

Several presentations at R4P 2018 looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates. They highlighted the urgency for new trial designs, using new endpoints and statistical approaches, given the ethical need for control arms to include oral PrEP as a standard of care. By definition, this reduces the number of people likely to become HIV positive compared to earlier placebo controlled studies.

October 24, 2018
i-base